Results 61 to 70 of about 24,654 (177)

Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells

open access: yesJournal of Pharmacological Sciences, 2015
Imatinib, a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit and PDGFR.
Yuming Wei   +2 more
doaj   +1 more source

Gramicidin Inhibits Lung Cancer Metastasis by Suppressing the ABL‐MMP9 Signaling Axis

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 11, November 2026.
Gramicidin inhibits ABL expression in lung cancer cells, promoting the downregulation of MMP9 expression. Blockade of the ABL–MMP9 signaling axis attenuates the migration and invasion capacity of cancer cells, ultimately suppressing lung metastasis. ABSTRACT Lung cancer, the deadliest malignant tumor worldwide, consists predominantly of non‐small cell ...
Xiuying Li, Ling Chen
wiley   +1 more source

Cytoreductive therapy reduces JAK2V617F+ blood velocity and adhesion to activated endothelium

open access: yes
British Journal of Haematology, EarlyView.
Angelica DaSilva   +8 more
wiley   +1 more source

Protein Lactylation in Cancer: From Mechanisms to Therapy

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Increased glycolysis and lactate accumulation promote histone and nonhistone protein lactylation, linking tumor metabolic reprogramming to treatment adaptation. Lactylation enhances DNA repair, suppresses antitumor immunity, strengthens antioxidant defenses, and facilitates cell‐cycle checkpoint escape, collectively promoting resistance to chemotherapy,
Wentian Huang   +8 more
wiley   +1 more source

An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders

open access: yesGenetics and Molecular Biology, 2007
In this work, we describe the advantages of multiplex-PCR in the specific detection of BCR-ABL transcripts in different hematological disorders and its sensitivity compared to nested PCR.
Darío A. Sastre   +5 more
doaj   +1 more source

Patterns of multimodal MRD response and toxicity with blinatumomab and tyrosine kinase inhibitors in Philadelphia‐positive acute B‐lymphoblastic leukaemia

open access: yes
British Journal of Haematology, EarlyView.
Sebastian M. Stolz   +6 more
wiley   +1 more source

Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo   +8 more
wiley   +1 more source

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

open access: yesHaematologica, 2003
BACKGROUND AND OBJECTIVES: Imatinib mesylate (IM) is the choice treatment for Bcr/Abl-positive malignancies. Emergence of resistance to IM warrants the exploration of novel well-tolerated anticancer agents. We intended to evaluate the effect of PS-341 on
S Gatto   +12 more
doaj  

RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia

open access: yeseLife
Philadelphia chromosome-positive (Ph+) leukemia is a fatal hematological malignancy. Although standard treatments with tyrosine kinase inhibitors (TKIs) have achieved remarkable success in prolonging patient survival, intolerance, relapse, and TKI ...
Mengya Zhao   +10 more
doaj   +1 more source

p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia

open access: yesHaematologica, 2012
Background The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome. The p185BCR/ABL or the p210BCR/ABL fusion proteins are encoded as a result
Afsar A. Mian   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy